3 years ago

The Cost-effectiveness of Corticosteroids for the treatment of Community-Acquired Pneumonia

Elina Eleftheria Pliakos, Nikolaos Andreatos, Giannoula S. Tansarli, Panayiotis D. Ziakas, Eleftherios Mylonakis

Publication date: Available online 15 November 2018

Source: Chest

Author(s): Elina Eleftheria Pliakos, Nikolaos Andreatos, Giannoula S. Tansarli, Panayiotis D. Ziakas, Eleftherios Mylonakis


The use of corticosteroids as adjunct treatment for community-acquired pneumonia (CAP) is associated with potential clinical benefits and the aim of this study was to evaluate the cost-effectiveness of this approach.


We constructed a decision-analytic model comparing the use of corticosteroids+antibiotics to that of placebo+antibiotics for the treatment of CAP. Cost-effectiveness was determined by calculating deaths averted and incremental cost-effectiveness ratios (ICER). Uncertainty was addressed by plotting cost-effectiveness planes and acceptability curves for various willingness-to-pay thresholds.


In the base-case analysis, corticosteroids with antibiotics resulted in savings of $142,795 per death averted (ICER: $-142,795/death averted). In the probabilistic analysis, at a willingness-to-pay of $50,000, corticosteroids with antibiotics had a 86.4% chance of being cost-effective compared to placebo with antibiotics. In cost-effectiveness acceptability curves, the corticosteroids+antibiotics strategy was cost-effective in 87.6% to 94.3% of simulations compared to the placebo with antibiotics strategy for a willingness-to-pay ranging from $0 to $50,000. In patients with severe CAP (PSI classes IV/V) the corticosteroids+antibiotics strategy resulted in savings of $70,587 and had a 82.6% chance of being cost-effective compared to the placebo+antibiotics strategy.


The use of corticosteroids with antibiotics is a cost-effective strategy and results in considerable health care cost-savings, especially among patients with severe CAP (PSI classes IV/V).

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.